



030

6400

H.C.

Dkt. 54927-A-PCT-US/JPW/ADM

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michael Konkel, et al.  
U.S. Serial No. : 09/764,710  
Filed : January 17, 2001  
For : COMPOUNDS SPECIFIC FOR THE HUMAN  
Alpha<sub>1d</sub> ADRENERGIC RECEPTOR AND USES  
THEREOF

1185 Avenue of the Americas  
New York, New York 10036  
April 16, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(b)(1) to supplement the Information Disclosure Statement filed on February 12, 2001.

Applicants submit this Supplemental Information Disclosure Statement in accordance with their duty of disclosure under 37 C.F.R. §1.56 in connection with the above-identified application.

According to 37 C.F.R. §1.97(b)(1), an Information Disclosure Statement shall be considered by the U.S. Patent and Trademark Office if filed within three months of the filing date of a national application. Applicants are filing this Supplemental Information Disclosure Statement within three months of the January 17, 2001 filing date of the subject application.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit 1**) and attached hereto as **Exhibits 2-3**:

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page: 2

1. PCT International Publication No. WO 99/57131, published November 11, 1999 (**Exhibit 2**); and
2. Snowball, R.K. et al. Investigation of the role of  $\alpha_{1A}$ - and  $\alpha_{1D}$ - adrenoceptors in the control of the "micturition reflex" in the anaesthetized male rat. British Journal of Pharmacology, Proceedings of the British Pharmacology Society Meeting January 5-7, 2000, Abstract 35P (**Exhibit 3**).

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would also like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit 1**) and which were previously cited in connection with the prosecution of U.S. Serial No. 09/118,323 or PCT International Application No. PCT/US99/16101, from the filing dates of which the subject application claims benefit under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement.

1. U.S. Patent No. 3,398,151, issued August 20, 1968, Wu;
2. U.S. Patent No. 3,558,777, issued January 26, 1971, Wu;
3. U.S. Patent No. 4,988,700, issued January 29, 1991, Traber et al.;
4. U.S. Patent No. 5,070,102, issued December 3, 1991, Traber et al.;

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page: 3

5. U.S. Patent No. 5,096,908, issued March 17, 1992, Gidda and Schaus;
6. U.S. Patent No. 5,155,128, issued October 13, 1992, Traber et al.;
7. U.S. Patent No. 5,200,410, issued April 6, 1993, Traber et al.;
8. U.S. Patent No. 5,258,379, issued November 2, 1993, Gidda and Schaus;
9. U.S. Patent No. 5,294,619, issued March 15, 1994, Nagel;
10. European Patent Application No. 0 372 776, published June 13, 1990, Nagel;
11. European Patent Application No. 0 395 312, published October 31, 1990, Cliffe;
12. European Patent Application No. 0 447 345, published September 18, 1991, Orjales-Venero and Rodes-Solanes;
13. European Patent Office No. 0 455 510, published November 6, 1991, Gidda and Schaus;
14. German Patent DE 40 39 631, published June 17, 1992;
15. Goetz, A.S. et al., BMY 7378 is a selective antagonist of the D subtype of  $\alpha_1$ -adrenoceptors. Eur. J. Pharmacol. (1995) 272: R5-R6;

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page: 4


16. Lopez-Rodriguez et al., 1-[ $\omega$ (4-Arylpiperazin-1-yl)alkyl]-3-diphenylmethylene-2,5-pyrrolidinediones as 5-HT<sub>1A</sub> receptor ligands: study of the steric requirements of the terminal amide fragment on 5-HT<sub>1A</sub> affinity/selectivity. *Bioorganic & Medicinal Chemistry Letters* (1998) 8: 581-586;
17. Saussy, D.L. Jr. et al., Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: Further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. *J. Pharmacol. Exp. Ther.* (1996) 278: 136-144; and
18. Wu, Y.-H. et al., Psychosedative agents. N-(4-Phenyl-1-piperazinylalkyl)-substituted cyclic imides. *J. Med. Chem.* (1969) 12: 876-881.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Michael Konkel, et al.  
Serial No.: 09/764,710  
Filed: January 17, 2001  
Page: 5


No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully Submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.



John P. White

4/16/01

Date

Reg. No. 28,678